Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Income from Continuing Operations: 2016-2024

Historic Income from Continuing Operations for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to -$260.6 million.

  • Rhythm Pharmaceuticals' Income from Continuing Operations fell 21.23% to -$52.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$192.3 million, marking a year-over-year increase of 25.72%. This contributed to the annual value of -$260.6 million for FY2024, which is 41.11% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Income from Continuing Operations stood at -$260.6 million for FY2024, which was down 41.11% from -$184.7 million recorded in FY2023.
  • Rhythm Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$69.6 million for FY2021, and its period low was -$260.6 million during FY2024.
  • Moreover, its 3-year median value for Income from Continuing Operations was -$184.7 million (2023), whereas its average is -$208.8 million.
  • Data for Rhythm Pharmaceuticals' Income from Continuing Operations shows a maximum YoY plummeted of 160.18% (in 2022) over the last 5 years.
  • Rhythm Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$69.6 million in 2021, then slumped by 160.18% to -$181.1 million in 2022, then fell by 1.97% to -$184.7 million in 2023, then plummeted by 41.11% to -$260.6 million in 2024.